EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Sex-specific and age-adjusted prevalence of hidradenitis suppurativa: Results from Komodo US claims data suggest sex parity of HS symptoms

Hadar Lev-Tov, John Ingram, Jennifer Hsiao, Maria Aleshin, Barry McGrath, Shawn Rajan, Nersi Alaeddin, ‘Matladi Ndlovu, Amit Garg

SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s851

DOI: 10.25251/5w5ny305 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that negatively impacts patients’ quality of life.1 HS has traditionally been reported to have a female predominance of approximately 3:1.2,3 Improving HS prevalence estimates may support better treatment outcomes.4 Here, the annual prevalence and sex distribution of diagnosed HS vs HS-related symptom-defined disease are reported using Komodo Health US claims data.5 Procedure/study: This study is a retrospective, real-world analysis of US secondary healthcare claims data from the Komodo Health database with >300 million patients selected from October 2016 to December 2024. Age-adjusted sex-specific annual prevalence data are reported from 2017 to 2024 for two mutually exclusive groups: patients with an ICD-10-based HS diagnosis and those with HS-related symptom-defined disease, coded on or after October 1, 2016. HS diagnosis was defined as presence of ICD-10 code L73.2.6 HS-related symptom-defined disease was based on the presence of ≥5 claims on distinct dates of HS-related symptoms, including abscess, furuncle and pilonidal cyst. This definition allowed identification of patients with recurrent HS-related manifestations in the absence of a formal HS diagnosis. Patients with ≥5 claims of solely pilonidal cyst were excluded. Age was assessed at the date of the first diagnosis or fifth HS-related symptom claim. All analyses are descriptive. Results: Approximately 2.4 million patients were included in the analysis; of these, ~1.6 million had an HS diagnosis and ~0.8 million had HS-related symptom-defined disease. In 2017, the prevalence of diagnosed HS was 62 and 148 cases per 100,000 population among males and females, respectively. This female predominance persisted through 2024, reaching 97 and 253 cases per 100,000 population among males and females, respectively. In contrast, HS-related symptom-defined disease exhibited a more balanced sex prevalence with a slight male predominance, with 43 and 37 cases per 100,000 population in 2017 and 67 and 54 per 100,000 population in 2024 among males and females, respectively. Conclusion: A similar prevalence of HS-related symptoms in the absence of a formal HS diagnosis was observed between sexes, contrary to current knowledge that HS prevalence is markedly higher among females than males. These findings may suggest underdiagnosis in males and highlight the need to reduce diagnostic disparities between male and female patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →